Literature DB >> 21459318

Is growth hormone resistance/IGF-1 reduction good for you?

Emily Jane Gallagher1, Derek LeRoith2.   

Abstract

GH, IGF-1, and insulin are emerging as important and independent mediators of tumor development and aging. Two recent studies report that humans with GH-receptor deficiency are protected from developing cancer through alterations in GH, IGF-1, and insulin signaling, decreasing the susceptibility of cells to DNA damage and abnormal proliferation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID： 21459318     DOI： 10.1016/j.cmet.2011.03.003

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  10 in total

1.  Short-term, supra-physiological rhGH administration induces transient DNA damage in peripheral lymphocytes of healthy women.

Authors:  C Fantini; P Sgrò; M Pittaluga; A de Perini; I Dimauro; A Sartorio; D Caporossi; L Di Luigi
Journal:  J Endocrinol Invest       Date:  2017-02-16       Impact factor: 4.256

2.  Plant-Based Diet and IGF-1 Modulation on HER2-Positive Breast Cancer: A Lifestyle Medicine Nutrition Approach in Oncology.

Authors:  Laurinda M F R Simões; Nelson A R Tavares; Cíntia Ferreira-Pêgo
Journal:  Am J Lifestyle Med       Date:  2021-06-19

3.  Simvastatin impairs growth hormone-activated signal transducer and activator of transcription (STAT) signaling pathway in UMR-106 osteosarcoma cells.

Authors:  María Claudia Sandoval-Usme; Adriana Umaña-Pérez; Borja Guerra; Octavio Hernández-Perera; Orlando Hernández-Perera; José Manuel García-Castellano; Leandro Fernández-Pérez; Myriam Sánchez-Gómez
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

4.  Superoxide anion radicals induce IGF-1 resistance through concomitant activation of PTP1B and PTEN.

Authors:  Karmveer Singh; Pallab Maity; Linda Krug; Patrick Meyer; Nicolai Treiber; Tanja Lucas; Abhijit Basu; Stefan Kochanek; Meinhard Wlaschek; Hartmut Geiger; Karin Scharffetter-Kochanek
Journal:  EMBO Mol Med       Date:  2015-01       Impact factor: 12.137

5.  Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma.

Authors:  Huizhen Nie; Jun Li; Xiao-Mei Yang; Qing-Zhen Cao; Ming-Xuan Feng; Feng Xue; Lin Wei; Wenxin Qin; Jianren Gu; Qiang Xia; Zhi-Gang Zhang
Journal:  Hepatology       Date:  2015-08-04       Impact factor: 17.425

Review 6.  Insulin-Like Growth Factors in the Pathogenesis of Neurological Diseases in Children.

Authors:  Raili Riikonen
Journal:  Int J Mol Sci       Date:  2017-09-26       Impact factor: 5.923

7.  Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma.

Authors:  Ramadevi Subramani; Rebecca Lopez-Valdez; Alyssa Salcido; Thiyagarajan Boopalan; Arunkumar Arumugam; Sushmita Nandy; Rajkumar Lakshmanaswamy
Journal:  Exp Mol Med       Date:  2014-10-10       Impact factor: 8.718

8.  Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations.

Authors:  Yongde Luo; Chaofeng Yang; Min Ye; Chengliu Jin; James L Abbruzzese; Mong-Hong Lee; Sai-Ching J Yeung; Wallace L McKeehan
Journal:  Cancer Metab       Date:  2013-11-25

9.  Dissociation of somatic growth, time of sexual maturity, and life expectancy by overexpression of an RGD-deficient IGFBP-2 variant in female transgenic mice.

Authors:  Andreas Hoeflich; Anja Reyer; Daniela Ohde; Nancy Schindler; Julia Brenmoehl; Marion Spitschak; Martina Langhammer; Armin Tuchscherer; Elisa Wirthgen; Ingrid Renner-Müller; Rüdiger Wanke; Friedrich Metzger; Maximilian Bielohuby; Eckhard Wolf
Journal:  Aging Cell       Date:  2015-10-28       Impact factor: 9.304

10.  Investigation of IGF1, IGF2BP2, and IGFBP3 variants with lymph node status and esophagogastric junction adenocarcinoma risk.

Authors:  Weifeng Tang; Shuchen Chen; Jun Liu; Chao Liu; Yafeng Wang; Mingqiang Kang
Journal:  J Cell Biochem       Date:  2018-10-18       Impact factor: 4.429
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.